- Home
- AS vs CTLT Comparison
AS vs CTLT Comparison
Compare AS & CTLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AS
- CTLT
- Stock Information
- Founded
- AS 1950
- CTLT 2007
- Country
- AS Finland
- CTLT United States
- Employees
- AS N/A
- CTLT N/A
- Industry
- AS
- CTLT Biotechnology: Pharmaceutical Preparations
- Sector
- AS
- CTLT Health Care
- Exchange
- AS NYSE
- CTLT Nasdaq
- Market Cap
- AS 9.5B
- CTLT 11.0B
- IPO Year
- AS 2024
- CTLT 2014
- Fundamental
- Price
- AS $19.31
- CTLT $59.12
- Analyst Decision
- AS Buy
- CTLT Hold
- Analyst Count
- AS 14
- CTLT 7
- Target Price
- AS $19.57
- CTLT $59.83
- AVG Volume (30 Days)
- AS 1.8M
- CTLT 1.9M
- Earning Date
- AS 11-19-2024
- CTLT 11-05-2024
- Dividend Yield
- AS N/A
- CTLT N/A
- EPS Growth
- AS N/A
- CTLT N/A
- EPS
- AS N/A
- CTLT N/A
- Revenue
- AS $4,638,000,000.00
- CTLT $4,422,000,000.00
- Revenue This Year
- AS $19.93
- CTLT $8.58
- Revenue Next Year
- AS $13.21
- CTLT $7.95
- P/E Ratio
- AS N/A
- CTLT N/A
- Revenue Growth
- AS 17.32
- CTLT 4.71
- 52 Week Low
- AS $10.11
- CTLT $36.74
- 52 Week High
- AS $20.68
- CTLT $61.20
- Technical
- Relative Strength Index (RSI)
- AS 56.37
- CTLT 45.31
- Support Level
- AS $17.84
- CTLT $59.34
- Resistance Level
- AS $20.68
- CTLT $60.21
- Average True Range (ATR)
- AS 0.81
- CTLT 0.52
- MACD
- AS 0.02
- CTLT 0.02
- Stochastic Oscillator
- AS 57.78
- CTLT 43.08
About AS AMER SPORTS INC
Amer Sports manages a diverse portfolio of 10 outdoor and action sports brands that collectively generated revenue of $4.4 billion in 2023. Although primarily owned by the Chinese conglomerate Anta Sports, Amer operates with a degree of autonomy. In its rapidly expanding China business, the company is subject to closer oversight, but it manages its operations outside of China with relative independence. In 2023, the firm generates 40% of its revenue from the Americas, 33% from Europe, the Middle East, and Africa, 19% from China, and 7% from Asia-Pacific, excluding China.
About CTLT Catalent Inc.
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.